Alaunos Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Fort Lauderdale, FL
SEC filing record 1 source field available
Fiscal year end
31 December
Alaunos Therapeutics, Inc. has filed 1,290 SEC EDGAR filings since 13 Feb 2001

SEC filing history

Showing 801-825 of 1,000 matching filings.

Per page
25
Current page
33
8-K File 001-33038

FORM 8-K

Filing date
31 Jan 2013
Reporting date
25 Jan 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33038

CURRENT REPORT

Filing date
08 Jan 2013
Reporting date
08 Jan 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
5

FORM 5 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
02 Jan 2013
Reporting date
31 Dec 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-185433

FORM S-8

Filing date
12 Dec 2012
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
D File 021-187344

D filing

Filing date
21 Nov 2012
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
09 Nov 2012
Reporting date
07 Nov 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-79364

RANDAL J KIRK SC13DA #4 11-7-2012 (ZIOPHARM ONCOLOGY, INC)

Filing date
09 Nov 2012
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33038

CURRENT REPORT

Filing date
08 Nov 2012
Reporting date
25 Oct 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33038

FORM 8-K

Filing date
08 Nov 2012
Reporting date
08 Nov 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33038

FORM 8-K

Filing date
19 Oct 2012
Reporting date
19 Oct 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33038

FORM 8-K

Filing date
07 Sep 2012
Reporting date
07 Sep 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q/A File 001-33038

FORM 10-Q/A

Filing date
28 Aug 2012
Reporting date
30 Jun 2012
Next action
Verify source filing
8-K File 001-33038

CURRENT REPORT

Filing date
02 Aug 2012
Reporting date
02 Aug 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 001-33038

QUARTERLY REPORT

Filing date
02 Aug 2012
Reporting date
30 Jun 2012
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .